JP2015502958A5 - - Google Patents

Download PDF

Info

Publication number
JP2015502958A5
JP2015502958A5 JP2014546103A JP2014546103A JP2015502958A5 JP 2015502958 A5 JP2015502958 A5 JP 2015502958A5 JP 2014546103 A JP2014546103 A JP 2014546103A JP 2014546103 A JP2014546103 A JP 2014546103A JP 2015502958 A5 JP2015502958 A5 JP 2015502958A5
Authority
JP
Japan
Prior art keywords
subject
effective amount
therapeutically effective
pathway inhibitor
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014546103A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015502958A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/068351 external-priority patent/WO2013086260A2/en
Publication of JP2015502958A publication Critical patent/JP2015502958A/ja
Publication of JP2015502958A5 publication Critical patent/JP2015502958A5/ja
Pending legal-status Critical Current

Links

JP2014546103A 2011-12-09 2012-12-07 がんの処置のための併用療法 Pending JP2015502958A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161568844P 2011-12-09 2011-12-09
US61/568,844 2011-12-09
US201261698030P 2012-09-07 2012-09-07
US61/698,030 2012-09-07
PCT/US2012/068351 WO2013086260A2 (en) 2011-12-09 2012-12-07 Combination therapy for treatment of cancer

Publications (2)

Publication Number Publication Date
JP2015502958A JP2015502958A (ja) 2015-01-29
JP2015502958A5 true JP2015502958A5 (enExample) 2016-02-04

Family

ID=48575059

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014546103A Pending JP2015502958A (ja) 2011-12-09 2012-12-07 がんの処置のための併用療法

Country Status (4)

Country Link
US (1) US20150132301A1 (enExample)
EP (1) EP2788378A4 (enExample)
JP (1) JP2015502958A (enExample)
WO (1) WO2013086260A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6081995B2 (ja) 2011-06-17 2017-02-15 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 癌の処置における治療抗体の標的としてのＦｒｉｚｚｌｅｄ２
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
WO2015009851A1 (en) * 2013-07-16 2015-01-22 Icahn School Of Medicine At Mount Sinai Methods of treating cancer in subjects afflicted with metabolic dysfunction
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
JP2017501137A (ja) * 2013-12-02 2017-01-12 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターに関連する予測バイオマーカーの同定
WO2015145388A2 (en) * 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
EP2975047A1 (en) * 2014-07-18 2016-01-20 Université de Lausanne Wnt7a polypeptides and their use
US20180244783A1 (en) * 2015-08-31 2018-08-30 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
MX393780B (es) 2017-01-17 2025-03-24 Heparegenix Gmbh Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos
JP2020514747A (ja) * 2017-03-16 2020-05-21 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｋｒａｓ陽性癌の診断法及び治療法
CN107441045B (zh) * 2017-07-21 2018-10-19 广州源生医药科技有限公司 用于递送Wnt信号通路抑制剂的脂质体制剂及其制备方法
MX2024000965A (es) * 2021-07-27 2024-02-09 Toray Industries Medicamento para el tratamiento y/o prevencion de cancer.
US20230383360A1 (en) * 2021-12-16 2023-11-30 D2G Oncology, Inc. Biomarkers for predicting responsiveness to mek inhibitor monotherapy and combination therapy

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142481A0 (en) * 2001-04-05 2002-03-10 Yissum Res Dev Co A method for identifying consitutively active mutants of mitogen activated protein kinases (mapk) and uses thereof
NZ570381A (en) * 2006-02-09 2011-02-25 Daiichi Sankyo Co Ltd Anti-cancer pharmaceutical composition
RU2009114745A (ru) * 2006-09-19 2010-10-27 Новартис АГ (CH) Биомаркеры, предназначенные для выявления направленной модуляции, эффективности ингибиторов raf, применения с целью диагностики и/или прогнозирования
WO2008115890A2 (en) * 2007-03-19 2008-09-25 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
CA2686484A1 (en) * 2007-05-11 2008-11-20 Bayer Schering Pharma Aktiengesellschaft Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity
EP2164850B1 (en) * 2007-06-12 2016-01-13 Genentech, Inc. N-substituted azaindoles and methods of use
US8053574B2 (en) * 2007-07-18 2011-11-08 Novartis Ag Organic compounds
CN101808516B (zh) * 2007-07-30 2013-08-28 阿迪生物科学公司 作为mek抑制剂的包括多晶型物的n-(芳氨基)磺酰胺衍生物和组合物、其使用方法和制备方法
CA2694646C (en) * 2007-07-30 2017-09-05 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
CN101854924A (zh) * 2007-11-05 2010-10-06 诺瓦提斯公司 测量wnt活化以及治疗wnt相关癌症的方法和组合物
CA2705452C (en) * 2007-11-12 2016-05-31 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
AU2009296246B2 (en) * 2008-09-26 2015-07-30 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
BRPI1009448A2 (pt) * 2009-03-11 2016-03-01 Ardea Biosciences Inc combinações farmacêuticas compreendendo edea119/bay 869766 para o tratamento de cânceres específicos
US8466155B2 (en) * 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
TWI535445B (zh) * 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
MX343368B (es) * 2010-03-09 2016-11-01 The Broad Inst Inc * Metodo de diagnostico y tratamiento de cancer en pacientes que tienen o desarrollan resistencia a una primera terapia de cancer.
CN102971337B (zh) * 2010-04-01 2016-09-21 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
US20120231965A1 (en) * 2011-02-03 2012-09-13 Prometheus Laboratories Inc. Drug selection for colorectal cancer therapy using antibody-based arrays
SI2672967T1 (sl) * 2011-02-07 2018-12-31 Plexxikon Inc. Spojine in postopki za kinazno modulacijo in indikacije zanjo

Similar Documents

Publication Publication Date Title
JP2015502958A5 (enExample)
IL274318A (en) Cancer treatment with rapamycin target site kinase inhibitors
HUE036583T2 (hu) Notch jelzõ folyamat inhibitorai és alkalmazásuk rákok kezelésében
PT2763982T (pt) Benzimidazois substituídos para utilização como inibidores da bub1 quinase no tratamento de doenças hiperploriferativas
HUE040044T2 (hu) Fumarátok prodrugjai, és azok alkalmazása különbözõ betegségek kezelésében
PL3489261T3 (pl) Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
IL243976B (en) kdm1a inhibitors for disease treatment
WO2015003360A3 (en) Therapeutically active compounds and their methods of use
ZA201402771B (en) Treatment of cancer with tor kinase inhibitors
PT3418281T (pt) Pirazolo[1,5-a]pirimidinas úteis como inibidores da quinase atr para o tratamento de doenças de cancro
EP2911669C0 (en) SYNERGIC COMBINATION OF IMMUNOLOGICAL INHIBITORS FOR THE TREATMENT OF CANCER
HK1216175A1 (zh) 治療性化合物和組合物
EP3065549A4 (en) Methods for inhibiting tie2 kinase useful in the treatment of cancer
HRP20181462T1 (hr) Kombinacija regorafeniba i acetilsalicilne kiseline za liječenje raka debelog crijeva
PL3004108T3 (pl) Pochodne pirazolo-pirolidyn-4-onu jako inhibitory BET oraz ich zastosowanie w leczeniu chorób
MX366317B (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
ZA201406706B (en) Treatment of cancer with tor kinase inhibitors
SG11201405686PA (en) Treatment of cancer with tor kinase inhibitors
PL2945642T3 (pl) Białko czynnika 1 do zastosowania w leczeniu lub zapobieganiu chorobom
ZA201607740B (en) Treatment of the complications of chronic liver disease with caspase inhibitors
PL3456333T3 (pl) Zastosowanie inhibitora telomerazy imetelstatu do leczenia zespołu mielodysplastycznego
PL3466425T3 (pl) Zastosowanie pochodnych glutarimidu w leczeniu chorób eozynofilowych
IL234641A0 (en) Cancer treatment with rapamycin target site kinase inhibitors
HK1223924A1 (zh) 治疗活性化合物及其使用方法
EP3050884A4 (en) Novel chemical compounds (variants) and the use thereof to treat oncological diseases